Biostage appoints children's hospital surgeon to science board
Courtesy
Christine Finck.
Courtesy
James McGorry, CEO of Biostage.
Holliston biotech has appointed a Connecticut children’s hospital doctor to its scientific advisory board less than a month after the company closed on a $100,000 investment from the same hospital.
Christine Finck, the executive vice president and surgeon-in-chief at Connecticut Children’s Medical Center, will now take a seat on the board to help guide the company’s research into treating esophagus, bronchus and trachea ailments by bioengineering organ implants.
The company on Jan. 3 closed on a $4.2-million private investment, which included $4.1 million from a group of Chinese investors and $100,000 from Finck’s hospital.
Joseph Vacanti, who chairs the board, called Finck a pioneering researcher in regenerative medicine.
Finck will bring her practical knowledge of clinical challenges of esophageal atresia to the company’s organ implant technology, Vacanti said.
Biostage CEO Jim McGorry said the move represents the company’s mission to bring together the best scientific and surgical minds to help treat diseases of the throat.
Read more
Biostage names regenerative medicine expert to board
Biostage awarded up to $1.7M grant for preclinical study
WBJ Web Partners
Most Recent
Most Recent
0 Comments